Drug
En3835
En3835: highest development phase Phase 3, developed by Endo. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Endo
Trials
| Drug | Phase | Indication |
|---|---|---|
| EN3835 NCT03428750 | Phase 3 | Edematous Fibrosclerotic Panniculopathy (Cellulite) |
| EN3835 NCT04209530 | Phase 2 | Cellulite |
Latest
No recent events.
Follow En3835 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.